Stay Connected

GET UPDATES
Learn more about Strensiq® (asfotase alfa) and HPP.

Please enter the following information:

Thank you for signing up to receive the latest information about Strensiq® (asfotase alfa).

Your registration on Strensiq.com ensures that you will be among the first to receive news and updates about Strensiq and hypophosphatasia (HPP).

  • First name is required
  • Last name is required
  • Email address is required
  • Country is required
  • ZIP code is required

Patient education is key for setting expectations and reducing the risk of injection-site reactions (ISRs).

ISRs were the most common adverse reaction seen in Strensiq® clinical trials.1

63% of patients in Strensiq clinical trials experienced ISRs
  • The majority resolved within a week
  • One patient discontinued Strensiq due to ISRs
Some patients continued to experience ISRs throughout treatment

Proper injection technique may help reduce the risk of certain ISRs.1

To reduce the risk of lipohypertrophy and injection site atrophy:
  • Rotate injection sites
    • Do not inject repeatedly in same area
    • See full Prescribing Information for further guidance on preparation and administration of the injection
  • Advise the patient to read the Labeling and Instructions for Use
  • Avoid areas that are red, inflamed, or swollen
  • Advise patients about the most common side effects of Strensiq
 
 
 

Examples of ISRs in patients treated with Strensiq8

 
 
Erythema on the arm of a patient treated with Strensiq
Erythema
Discoloration on the abdomen of a patient treated with Strensiq
Discoloration
Lipohypertrophy on the abdomen of a patient treated with Strensiq
Lipohypertrophy
 

Indication

STRENSIQ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)1

Important Safety Information

  • Hypersensitivity reactions, including anaphylaxis, have been reported in STRENSIQ-treated patients. Signs and symptoms consistent with anaphylaxis included difficulty breathing, choking sensation, nausea, periorbital edema, and dizziness. These reactions have occurred within minutes after subcutaneous administration of STRENSIQ and can occur in patients on treatment for more than one year. Other hypersensitivity reactions have also been reported in STRENSIQ-treated patients, including vomiting, fever, headache, flushing, irritability, chills, skin erythema, rash, pruritus and oral hypoesthesia. If a severe hypersensitivity reaction occurs, discontinue STRENSIQ treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering STRENSIQ to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.
  • Localized lipodystrophy, including lipoatrophy and lipohypertrophy, has been reported at injection sites after several months in patients treated with STRENSIQ. Advise patients to follow proper injection technique and to rotate injection sites.
  • Patients with HPP are at increased risk for developing ectopic calcifications. In clinical trials, 14 cases (14%) of ectopic calcification of the eye including the cornea and conjunctiva, and the kidneys (nephrocalcinosis) were reported. There was insufficient information to determine whether or not the reported events were consistent with the disease or due to STRENSIQ. No visual changes or changes in renal function were reported. Ophthalmology examinations and renal ultrasounds are recommended at baseline and periodically during treatment with STRENSIQ to monitor for signs and symptoms of ophthalmic and renal ectopic calcifications and for changes in vision or renal function.
  • The most common adverse reactions (≥ 10%) are injection site reactions, lipodystrophy, ectopic calcifications and hypersensitivity reactions.